Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Increasing Number of Clinical Trials and Research Activities in the Gene Therapy Space
   3. Market Restraints
      1. Immune Response and Immunogenicity
      2. Limited Vector Capacity and Payload Constraints
   4. Market Opportunities
      1. Expansion of Indications and Therapeutic Applications Beyond Rare Genetic Disorders
   5. Market Trends
      1. Advancements in Capsid Engineering
      2. Diversification of Delivery Modalities
5. MARKET SEGMENTATION
   1. By Gene Therapy Application
      1. Neurological Disorders
      2. Ophthalmic Diseases
      3. Muscular Disorders
      4. Hematological Disorders
   2. By Adeno-Associated Virus Serotype
      1. AAV1
      2. AAV2
      3. AAV5
      4. AAV9
   3. By End-User
      1. Hospitals
      2. Research Institutes
      3. Biopharmaceutical Companies
   4. By Therapeutic Area
      1. Rare Diseases
      2. Oncology
      3. Cardiovascular Diseases
      4. Genetic Disorders
   5. By Distribution Channel
      1. Direct Tender
      2. Hospital Pharmacy
      3. Retail Pharmacy
      4. Online Pharmacy
      5. Others
   6. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Abeona Therapeutics
      2. Amicus Therapeutics
      3. Aldevron (acquired by Danaher)
      4. BioMarin Pharmaceutical
      5. Freeline Therapeutics
      6. NightstaRx Ltd.
      7. Oxford BioMedica
      8. Roche (Spark Therapeutics)
      9. Pfizer
      10. Regenxbio
      11. Sangamo
      12. Sarepta Therapeutics
      13. Solid Biosciences
      14. UniQure
      15. Voyager Therapeutics
   2. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapymarket?

The global market of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy is projected to reach USD 21.2Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapymarket?

The global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market has an estimated annual growth rate of 15.1%. 

Q.3. What are the recent trends of Adeno-Associated Virus (AAV) Vector-Based Gene Therapymarket?

Advancements in capsid engineering and diversification of delivery modalities are some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy?

The major companies profiled in this report include Abeona Therapeutics, Amicus Therapeutics, Aldevron (acquired by Danaher), BioMarin Pharmaceutical, Freeline Therapeutics, NightstaRx Ltd., Oxford BioMedica, Roche (Spark Therapeutics), Pfizer, Regenxbio, Sangamo, Sarepta Therapeutics, Solid Biosciences, UniQure, Voyager Therapeutics, among others.

Q.5. Which region is estimated to held highest CAGR inAdeno-Associated Virus (AAV) Vector-Based Gene Therapymarket?

North America is estimated to hold biggest share in the market for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy.